Abstract A recent study indicates that the protein Eya3 influences the adaptive immune response to promote tumor growth, not only decreasing the number of tumor-infiltrating CD8+ T cells, but also driving their exhaustion through PD-L1 upregulation. These findings could spur new strategies to treat triple-negative breast cancer, which currently lacks targeted therapies.